A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?
R Koide, S Kobayashi, T Shimohata… - Human molecular …, 1999 - academic.oup.com
To investigate whether the expansion of CAG repeats of the TATA-binding protein (TBP)
gene is involved in the pathogenesis of neurodegenerative diseases, we have screened 118 …
gene is involved in the pathogenesis of neurodegenerative diseases, we have screened 118 …
Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription
T Shimohata, T Nakajima, M Yamada, C Uchida… - Nature …, 2000 - nature.com
At least eight inherited neurodegenerative diseases are caused by expanded CAG repeats
encoding polyglutamine (polyQ) stretches. Although cytotoxicities of expanded polyQ …
encoding polyglutamine (polyQ) stretches. Although cytotoxicities of expanded polyQ …
[HTML][HTML] Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke
…, M Hatakeyama, T Takahashi, T Shimohata - International journal of …, 2017 - mdpi.com
Stroke is a leading cause of morbidity and mortality worldwide, and consists of two types,
ischemic and hemorrhagic. Currently, there is no effective treatment to increase the survival …
ischemic and hemorrhagic. Currently, there is no effective treatment to increase the survival …
Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats
H Zhao, T Shimohata, JQ Wang, G Sun… - Journal of …, 2005 - Soc Neuroscience
Activation of the Akt/protein kinase B (PKB) kinase pathway can be neuroprotective after stroke.
Akt is activated by growth factors via a phosphorylation-dependent pathway involving the …
Akt is activated by growth factors via a phosphorylation-dependent pathway involving the …
Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine …
S Igarashi, R Koide, T Shimohata, M Yamada… - Nature …, 1998 - nature.com
To elucidate the molecular mechanisms whereby expanded polyglutamine stretches elicit a
gain of toxic function, we expressed full-length and truncated DRPLA (dentatorubral-…
gain of toxic function, we expressed full-length and truncated DRPLA (dentatorubral-…
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial
…, S Tsuji, K Hasegawa, T Shimohata… - The Lancet …, 2010 - thelancet.com
Background Spinal and bulbar muscular atrophy is a hereditary motor neuron disease caused
by the expansion of a polyglutamine tract in the androgen receptor. At present there are …
by the expansion of a polyglutamine tract in the androgen receptor. At present there are …
COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion
…, Y Sahashi, Y Baba, H Okura, T Shimohata - Journal of the …, 2020 - jns-journal.com
Discussion Here we presented novel neurological manifestations of COVID-19. First, we
demonstrated the patients with COVID-19 might show an isolated SCC lesion on brain MRI. …
demonstrated the patients with COVID-19 might show an isolated SCC lesion on brain MRI. …
Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study
M Kanazawa, T Shimohata… - … : official journal of the …, 2009 - Wiley Online Library
The clinical heterogeneity of progressive supranuclear palsy (PSP), which is classified as
classic Richardson's syndrome (RS) and PSP‐Parkinsonism (PSP‐P), has been previously …
classic Richardson's syndrome (RS) and PSP‐Parkinsonism (PSP‐P), has been previously …
Clinical characteristics of autoimmune GFAP astrocytopathy
…, N Yoshikura, Y Hayashi, T Shimohata - Journal of …, 2019 - Elsevier
The clinical features of autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
remain to be elucidated. We describe here the clinical features of 14 patients with GFAP …
remain to be elucidated. We describe here the clinical features of 14 patients with GFAP …
Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications
T Kanbayashi, T Shimohata, I Nakashima… - Archives of …, 2009 - jamanetwork.com
Objective To characterize factors that contribute to symptomatic narcolepsy and excessive
daytime sleepiness in neuromyelitis optica and multiple sclerosis. Setting Japanese university …
daytime sleepiness in neuromyelitis optica and multiple sclerosis. Setting Japanese university …